(MENAFN- GlobeNewsWire - Nasdaq) The global portal hypertension drugs market is thriving due to rising liver disease rates, particularly cirrhosis and hepatitis, and an aging global population, leading to heightened demand for effective therapies. Key players like Gilead Sciences and Novartis are driving market growth through innovation and strategic partnerships. Despite challenges such as high treatment costs and limited access, ongoing R&D aims to introduce affordable solutions. As awareness of liver health expands, technological advancements and increased healthcare investments, especially in the U.S. and Europe, will fuel further market expansion.

Dublin, Nov. 19, 2025 (GLOBE NEWSWIRE) -- The "Portal Hypertension Drugs Market - A Global and Regional Analysis: Focus on Country and Regional Analysis - Analysis and Forecast, 2025-2035" report has been added to ResearchAndMarkets's offering.
The competitive landscape of the global portal hypertension drugs market is dynamic, with key players such as Gilead Sciences, Inc., Ono Pharmaceutical Co., Ltd., Novartis AG, and Conatus Pharmaceuticals Inc., driving market innovation through strategic partnerships, product diversification, and continuous investment in research. These companies are focusing on expanding their portfolios to meet the growing demand for more effective and convenient treatment options for portal hypertension. Their emphasis on novel drug development and combination therapies will play a crucial role in shaping the future of the global portal hypertension drugs market.
The rising prevalence of liver diseases, especially cirrhosis and chronic hepatitis, is a key driver of the portal hypertension drugs market. These conditions cause elevated pressure in the portal vein, leading to complications like variceal bleeding and ascites. As the global incidence of liver diseases increases, the need for effective management solutions for portal hypertension grows stronger.

Looking ahead, the global portal hypertension drugs market is driven by technological advancements and increased awareness of liver health. The development of new therapies, coupled with rising consumer demand for comprehensive healthcare solutions, will continue to drive market growth. The global portal hypertension drugs market is poised to play a critical role in the broader healthcare industry, significantly improving patient outcomes and contributing to global healthcare delivery.
The global portal hypertension drugs market is poised for steady growth, driven by continuous innovations in treatment options and enhanced therapeutic capabilities. Increased investments in healthcare infrastructure across the U.S., Europe, and emerging markets are expected to significantly contribute to the market's expansion. Advanced applications of medical treatments and pharmaceutical innovations will position the global portal hypertension drugs market.
Moreover, the global aging population is more vulnerable to chronic conditions, including liver diseases that can result in portal hypertension. As the elderly population expands, the occurrence of complications related to portal hypertension rises, boosting the demand for specialized treatments and healthcare services.
The increasing focus on liver health and the rising incidence of liver-related diseases in both developed markets, such as the U.S., and emerging economies, is a major driver behind the growth of the global portal hypertension drugs market. Moreover, the expanding aging population, particularly in regions such as the U.S. and Europe, is contributing to the rising prevalence of portal hypertension, further fueling the demand for targeted therapies.
However, despite these advancements, the global portal hypertension drugs market faces challenges, such as the high cost of advanced treatments and limited access to healthcare in underserved regions. Many individuals may not receive timely treatment due to cost barriers or a lack of access to specialized care. Additionally, delays in diagnosis and treatment initiation can lead to complications, increasing the burden on healthcare systems. Nevertheless, ongoing research and development by key industry players are expected to address these challenges by introducing more affordable and effective solutions for portal hypertension management.
Key Topics Covered:
Executive Summary
Scope and Definition
Market/Product Definition
Key Questions Answered
Analysis and Forecast Note
1. Global Portal Hypertension Drugs Market: Industry Outlook
1.1 Trends: Current and Future Impact Assessment
1.2 Epidemiological Analysis
1.3 Regulatory Landscape
1.4 Pipeline Analysis
1.5 Pricing Analysis
1.6 Market Dynamics
1.6.1 Market Drivers
1.6.1.1 Impact Analysis
1.6.2 Market Restraints
1.6.2.1 Impact Analysis
1.6.3 Market Opportunities
1.6.3.1 Impact Analysis
2. Global Portal Hypertension Drugs Market, by Region, $Million, 2024-2035
2.1 North America
2.1.1 Market Dynamics
2.1.2 Market Sizing and Forecast
2.1.2.1 North America Portal Hypertension Drugs Market (by Country)
2.1.2.1.1 U.S.
2.1.2.1.2 Canada
2.2 Europe
2.2.1 Market Dynamics
2.2.2 Market Sizing and Forecast
2.2.2.1 Europe Portal Hypertension Drugs Market (by Country)
2.2.2.1.1 Germany
2.2.2.1.2 France
2.2.2.1.3 U.K.
2.2.2.1.4 Spain
2.2.2.1.5 Italy
2.2.2.1.6 Rest-of-Europe
2.3 Asia-Pacific
2.3.1 Market Dynamics
2.3.2 Market Sizing and Forecast
2.3.2.1 Asia-Pacific Portal Hypertension Drugs Market (by Country)
2.3.2.1.1 Japan
2.3.2.1.2 Rest-of-Asia-Pacific
2.4 Rest-of-the-World
2.4.1 Market Dynamics
2.4.2 Market Sizing and Forecast
3. Global Portal Hypertension Drugs Market - Competitive Benchmarking & Company Profiles
3.1 Key Strategies and Development
3.1.1 Mergers and Acquisitions
3.1.2 Partnership, Alliances and Business Expansion
3.1.3 New Offerings
3.1.4 Regulatory Activities
3.1.5 Funding Activities
3.2 Company Profiles
3.2.1 Overview
3.2.2 Top Products/Product Portfolio
3.2.3 Top Competitors
3.2.4 Target Customers
3.2.5 Key Personnel
3.2.6 Analyst View

• Novartis AG
• Conatus Pharmaceuticals Inc.
• Ono Pharmaceutical Co., Ltd.
• Galectin Therapeutics, Inc.
• Alfasigma (Intercept Pharmaceuticals, Inc.)
• Mezzion Pharma Co. Ltd.

For more information about this report visit

About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

CONTACT: CONTACT: Laura Wood,Senior Press Manager... For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

MENAFN19112025004107003653ID1110367399